Randomized Controlled Trial J Eur Acad Dermatol Venereol . 2012 Feb;26(2):219-25. doi: 10.1111/j.1468-3083.2011.04039.x. Epub 2011 Mar 24. Efficacy of blue light vs. red light in the treatment of psoriasis: a double-blind, randomized comparative study M M Kleinpenning 1, M E Otero, P E J van Erp, M J P Gerritsen, P C M van de … Read more
Nine psoriasis patients used 633 nm red and 830 nm infrared LED therapy on recalcitrant psoriasis. The majority had failed earlier treatments.
Seven patients show 60% to 100% clearance of psoriasis symptoms when measured from three to 8 months after treatment. Two of the subjects could not be located.
Researchers treated 25 psoriasis patients with psoralen and ultraviolet-A (PUVA), and another 25 patients with psoralent and ultraviolet-B (PUVB). Psoriasis affected 25-70% of the patient’s skin. After 8 weeks of treatment, 92% of the PUVA group, and 80% of the PUVB group had remission. Limbs and trunk were more resistant than the rest of the body. 28% of PUVA and 24% of PUVB suffered erythema (redness); 32% and 28% pruitis (itchiness); 28% and 24% nausea and vomiting; 16% and 12% fever & malaise; 12% and 16% headache; 1% and 0% blister; 1% and 0% claustrophobia. Researchers concluded that PUVA and PUVB had substantially similar positive outcomes.
Physician’s office treatment (not a home therapy) using Narrow Band Ultraviolet B (NB-UVB) for psoriasis patients affected on greater than 10% of the body and have not responded to other treatments. UVB is dangerous without safety precautions. The doctor uses an excimer laser. The patient is treated 2x-3x per week. Is potentially combined with “emollients, calcipotriene, cortico-steroids, retinoids, and tar. NB-UVB can be used in selected patients with traditional systemic agents such as methotrexate, mycophenolate mofetil, and cyclosporine…”